The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Matterhorn thank you for your reply.
The following may or may not explain why the NIH seem keen to accommodate Synairgen as opposed to just kicking them off the trial like with SAB.
There has been various examples of support over the last couple of years to suggest that the US Gov are keen on them. The relationship to the NIH itself, as far as known, dates back to MERS:
"At the time of the MERS-CoV outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the US to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro."
During COVID-19, there have been mentions about SNG001 made by Janet Wood****, Anthony Fauci and Davey Smith.
Therefore, I don't have too many concerns about the strength of the relationship between the US Gov and Synairgen. Like you, how they will make it work for Omicron is my big question.
Required redesign aside, I figure there could a few scenarios which will see the continuation of a trial:
+ they are waiting for next wave of Omicron (most likely BA.2) to hit, which should yield an increase hospitalisation rates.
+ they understand that there will be another variant of concern and the trial can resume once that wave hits: https://www.nature.com/articles/d41586-022-00510-y
+ an unlikely scenario, but not completely out of the question - the FDA see something within the SPRINTER deep dive analysis and in combination with P2 ACTIV-2 data, forces their hand to approve in the event of an urgent requirement for an effective therapy. That urgent need could arrive due to a worrying variant which once again renders a current generation of mABs useless. I must stress that this is a real long shot at this point but I can't rule it out.
Whichever case, the NIH are going to have be quick to adapt the trial accordingly. Ideally, they will have different designs for different scenarios.
How much does smoke cost these days?
Haven't bought some myself for a long time, not since the 1980's when I thought it was cool to carry smoke around with me. I switched out in the 90's to steam but it just didn't have same coolness to it. Couldn't go back to smoke though as the coughing was too much and I was working as a priest in a very quiet church.
Would ignore antofelli / lesmiserable
Seen it time and time again where people like them lose a lot of cash, then spend their time trolling the share forum in which they lost money on. Everyone has a different way of handling this kind of situation, their's isn't very respectable and I suppose a reflection on their character. Gloating at other people's misfortune is as low as it gets.
In the meantime, I am buying the dips (as with the SAB news other day) and trading where possible. Somebody said that we know the share well enough to do this and I would have to agree. Still got my main holding but I think one can make some money until the next news - which will hopefully restore some positivity.
My form. This isn't the football.
Your post is ridiculous. Many are frustrated with the situation, including myself, but what you are insinuating is beyond stupid.
It is dignity, thought, plus the ability to write in coherent English which you are most certainly lacking in.
Tattyhead is very apt. Your entire head is "worn and shabby; in poor condition."
Long Covid also on the menu - something which Ray Jordan was very keen to make a point of in a recent webinar. The media is switching from vaccine coverage to treatment coverage, according to Jordan.
*Immunocompromised people will have priority for protections and treatments*
The road map also emphasizes making sure that people most at risk of severe illness from COVID-19 don't feel left behind as normal activities resume.
The White House says it will prioritize protections for people who are immunocompromised as well as those with disabilities and older adults, giving them priority access to treatments and pushing to make sure they get boosters.
There are also plans to provide support for people who have lost a loved one to the disease.
The White House wants Congress to reinstate tax credits to cover paid sick and family leave so people working at small- and medium-size businesses can stay home if they get COVID-19 or need to care for someone who has it, Zients said.
Health and Human Services Secretary Xavier Becerra told reporters his department needs funding to start centers of excellence for studying and treating long COVID-19.
https://www.npr.org/2022/03/02/1083905865/the-white-house-has-a-new-plan-for-covid-19-aimed-at-getting-things-back-to-norm?t=1646309668462
Great thread here: https://mobile.twitter.com/ASlavitt/status/1499113375619371008
Slavitt was temporary Senior Advisor to the COVID-19 Response Coordinator in the Biden administration.
Whilst "Emma" works themselves into a sweat over worrying about other investors, this was the biggest announcement from the States yesterday:
https://www.niaid.nih.gov/grants-contracts/peruse-pandemic-preparedness-plan
One of the highlights of the linked within PDF is:
"Recent advances in understanding host innate immunity highlight the potential value of non-antigenspecific protection as a bridge during development of antivirals and vaccines. NIAID will support the development and clinical evaluation of short-term, but broadly protective strategies including the use of inhaled or systemic immunomodulators."
Zooming in on "inhaled or systemic immunomodulators" - I only know of 1 inhaled immunomodulator.
The basic concept is that they want to be prepared for the next wave and the next variant. They want to be able to test people in a pharmacy and give them the treatment right away. That is known as the "Test & Treat" policy.
In particular, Biden on Tuesday emphasised that the new guidance and initiatives are not leaving behind immunocompromised people, who are at higher risk of severe COVID-19.
I don't blame NIH for not kicking SNG001 off.
Perhaps this offers a clue as to why Polygon keeping buying.
SPRINTER failed. Not the drug.
https://omicronb11529variant.com/weaker-omicron-variant-is-great-news-for-the-world-but-bad-news-for-covid-related-clinical-trials-endpoints-news/
"The only other drug that might still be actively enrolling participants was Synairgen’s inhalable beta interferon candidate. Neither the company nor NIH immediately offered comment."
Yes RM should speak but nobody should pay much attention to pond life like Mr Costs/Macosta. Half a million shares invested and barely a clue what he is talking about.
There are very few other posters posting here with such a constant stream of negativity. That applies to pre readout and post readout.
Doc - Jamie Dimon is actually a big name: https://en.wikipedia.org/wiki/Jamie_Dimon
Forum is very lucky to have him.
TLWilliams. - every single forum was equally as convinced at success of P3. I don't believe it was any different depending on which forum one visited. Equally so, every single forum is massively disappointed at the way things have turned out. I cannot see much positivity anywhere.
Under 'Exclusion Criteria'
Use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study.